Here’s a bold statement: Booster shots aren’t just a suggestion—they could be a lifesaver. A groundbreaking study involving over 3 million adults in England has revealed that COVID-19 booster vaccines significantly reduce the risk of hospitalization and death. But here’s where it gets even more intriguing: the research, led by the universities of Bristol and Oxford, shows that both Moderna and Pfizer-BioNTech boosters offer similar protection, though their effectiveness wanes over time. And this is the part most people miss: while boosters halved the risk of COVID-19-related hospitalization and death, they also showed a small, unexpected reduction in fracture risk, raising questions about confounding factors in the study design.
Published in Vaccine on February 18, the study analyzed data from the autumn 2022 booster campaign in England, focusing on adults aged 50 and older. Researchers compared 3.4 million boosted individuals with an equal number of unboosted individuals, matching them for age, vaccination history, clinical vulnerability, and geographical region. Over nearly a year, they tracked outcomes like hospitalizations, deaths, and even fractures—a seemingly unrelated metric that added a layer of complexity to the findings.
The results were striking: boosted individuals had a 350-day COVID-19 hospitalization risk of 3.78 per 1,000, compared to 6.81 per 1,000 for unboosted individuals. Similarly, the death risk dropped from 0.61 per 1,000 to 0.29 per 1,000. Protection was strongest in the first 70 days after vaccination, gradually declining thereafter. Interestingly, while both Moderna and Pfizer-BioNTech boosters performed similarly for COVID-19 outcomes, the Moderna group (mRNA-1273) saw slightly higher non-COVID-19 mortality, though the reasons remain unclear.
Controversially, the study’s fracture findings have sparked debate. The small reduction in fracture risk among boosted individuals suggests that not all confounding factors were fully accounted for. However, researchers argue that this minor effect actually strengthens the study’s validity, as it indicates the primary findings—reduced COVID-19 risks—are robust.
Dr. Paul Madley-Dowd, the study’s corresponding author, emphasized, “Our findings reinforce the importance of booster vaccination for those over 50, offering clear evidence of reduced hospitalization and death risks.” Funded by organizations like NHS England, the Wellcome Trust, and the NIHR, this research adds critical weight to the ongoing global vaccination efforts.
But here’s a thought-provoking question for you: If boosters are so effective, why do we still see hesitancy among certain groups? Is it misinformation, accessibility issues, or something else entirely? Let us know your thoughts in the comments—this is a conversation worth having.
